Celcuity was founded in 2012 by Brian Sullivan and Lance Laing, PhD, to develop a better way to diagnose and treat the cellular abnormalities that drive tumor growth. Celcuity’s platform provides unparalleled insights into oncogenic pathways. We are a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them. Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress. Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial. Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium. Our team of drug development scientists, biochemists, molecular biologists, and diagnostics experts are advancing new targeted therapies for cancer using an integrated therapeutic and companion diagnostic strategy that leverages our CELsignia platform. With our functional cellular analysis platforms, we are characterizing abnormal cell activity to identify other tumor types and non-oncology diseases that gedatolisib may be able to treat efficaciously.
Founded in 2012
11-50 Employees
Working industry
Other
Type of company
Educational institution
Number of products
1 Product
Specialised areas
Biotechnology, Health Care, Health Diagnostics, Therapeutics
Celcuity offers a wide range of products and services
Product
CELsignia platform - Celcuity
Go to product >
Some frequent questions that have been asked about Celcuity
How many employees does Celcuity approximately have?
As of the latest available information Celcuity has around 11-50 employees worldwide.
When was Celcuity founded?
Celcuity was founded in 2012
In which industries does Celcuity mainly work?
The company Celcuity has it's main focus in the industries of Other
Check out some interesting alternative companies to Celcuity
Celularity
Florham Park, United States
101-250 Employees
2017
At Celularity, we believe that by harnessing the placenta’s unique biology, ready availability and scalability, we can develop solutions for significant unmet global needs for effective, accessible, and affordable therapeutics. Celularity’s innovative approach harnesses the unique therapeutic potential locked within the cells and biomaterials of the postpartum placenta. Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases. BEST IN CLASS & SCALABLE Cellular Medicine manufacturing. ALLOGENEIC PLATFORM Built on two decades of science. INNOVATIVE PLACENTA-DERIVED T cells, NK Cells, and pluripotent stem cells. A fully integrated, purpose-built manufacturing, translational research and biobanking center.
CellPly
Bologna, Italy
11-50 Employees
2013
Cellply is a deep tech company with the ambition to develop analytical tools enabling fast end effective development of life-saving cancer cell therapies. Our team features a unique combination of expertise in a diverse set of technology going from microfluidics to robotics, AI, biology and immunology. During Advanced Therapies Week 2024 in Miami we officially launched our flagship product, VivaCyte®.
Celligent Diagnostics
Charlotte, United States
51-100 Employees
-
Celligent Diagnostics, is a high-complexity CLIA-certified clinical laboratory, that provides Histology, Cytology and pharma services specializing in cancer diagnostic testing. Celligent has mature working partnerships with several domestic and international research firms. Celligent offers a flexible and complete Cytology testing pallet for the Obstetrics and Gynecology industry. Celligent Diagnostics is committed to delivering innovative pathology services to meet the diagnostic needs of the medical community, and help improve patient care through timely and accurate pathology. Celligent Diagnostics is committed to delivering innovative pathology services to meet the diagnostic needs of the medical community, and help improve patient care through timely and accurate pathology. The Celligent Diagnostics Ancillary Testing Order Form provides our clients and referring locations with an easy-to-use web form users can complete from any device with an internet connection or take the tried and truth method and print, complete, scan and send back. We offer the clinical expertise of over 30 board certified pathologists covering multiple sub-specialties. Our testing menu provides in-house testing of over 200 IHC special stains, HR HPV-ISH testing and industry leading biomarkers such as PD-L1 testing.
Cellics Therapeutics
San Diego, United States
11-50 Employees
2014
Cellics Therapeutics leverages the multifaceted Cellular Nanoparticle (CNP™) technology to develop nano-therapeutics. Cellics’ dynamic nanoplatform, Cellular Nanosponges, harnesses the power of cell membranes to craft specialized nanoparticle-based therapeutics. Cellics is a privately held San Diego-based biopharmaceutical company founded by UC San Diego Professor Liangfang Zhang. We are honest with ourselves and transparent with our actions. We are tireless in applying scientific excellence to seek new solutions for big problems. We are inspired to take action, to be courageous, to break boundaries, for the well-being of patients. Cellics and UCSD have a close collaboration to further develop core platform technologies. Cellics and CARB-X have a strategic partnership of up to $15 Million to develop a novel macrophage nanosponge for treating sepsis.
MM18 Medical
Uppsala, Sweden
1-10 Employees
2018
Cellda is a Swedish company specializing in next generation algorithmic analysis in digital pathology. The aim is to obtain reproducible, correct and objective histo-pathological diagnoses of tissue sections with human cancer.
Cell X Technologies
Cleveland, United States
1-10 Employees
2017
Cell X is dedicated to advancing the promise of cellular therapies for innovators and patients alike. As Celligent operates, a wealth of invaluable data is gathered and stored in the CxKnowledge base. This comprehensive dataset is the bedrock for continuous advancements in Celligent's machine learning algorithm and is pivotal in establishing a program's proof of safety, efficacy, and reproducibility. With a passion for pushing the boundaries, our team has been purpose-built to foster an environment of innovation.
